# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT03716388 (Continued)

# Inclusion criteria

- UC diagnosis based on history of chronic (&gt; 4 weeks), inflammatory (with blood and mucus) diarrhea
- Total Mayo score 4–10, Mayo Endoscopic subscore &gt; 1
- Histopathology suggestive of UC

# Exclusion criteria

- Severe UC (Total Mayo score 11–12, Endoscopic Mayo score 3)
- Uncertainty about diagnosis of UC: infective colitis/indeterminate colitis/Crohn's colitis
- Associated IBS
- History of surgery or colorectal surgery
- Exposure to antibiotics or probiotics in last 4 weeks
- Evidence of infections (e.g. Clostridioides difficile, CMV, HIV, parasitic infections or extra-intestinal infections requiring antibiotics)
- Significant cardiopulmonary comorbidities (high risk for repeated colonoscopy)
- Pregnancy
- Refusal to consent for repeated colonoscopies

# Interventions

# Experimental arm

- FMT fresh sample, administered via colonoscopy at weeks 0, 2, 6, 10, and 14

# Control arm

- Mesalamine

# Outcomes

# Primary outcome

- Clinical remission (Mayo score ≤ 2, each subscore ≤ 1) at week 14

# Secondary outcomes

- Clinical response (reduction of Mayo score ≥ 30% and ≥ 3 points compared to baseline) at weeks 0, 2, 6, 10, and 14
- Endoscopic remission (Endoscopic Mayo subscore 0) at week 14
- Histologic remission (Nancy grade 0 or 1) at week 14

# Starting date

1 December 2018

# Contact information

Contact: Ajit Sood, DM

Dayanand Medical College and Hospital, Ludhiana, Punjab, India, 141001

# Notes

Phase 3 trial

# NCT03804931

# Study name

Fecal microbiota transplantation for ulcerative colitis

# Methods

RCT conducted in China

# Participants

# Inclusion criteria

- Adults with active, moderate-to-severe UC (Mayo score &gt; 6)
- "Safety using history of 5-ASA"
- Ability to undergo endoscopy examination

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.